Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin N Rome

Showing results (41-50 of 139) with videos related to

Pageof 14
Sort By:
JAMA Health Forum|March 31, 2023
Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021Anjali D Deshmukh, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 19, 2022
New Reforms to Prescription Drug Pricing in the US: Opportunities and ChallengesThomas J Hwang, Aaron S Kesselheim, Benjamin N Rome
JAMA Network Open|January 15, 2026
Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare PatientsJacob S Riegler, Aaron S Kesselheim, Benjamin N Rome
Health Affairs (Project Hope)|May 3, 2021
Frequency Of Generic Drug Price Spikes And Impact On Medicaid SpendingAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|September 23, 2024
Estimated Savings Under the Medicare High-Value Drug List ModelChristopher L Cai, Aaron S Kesselheim, Benjamin N Rome
The New England Journal of Medicine|October 16, 2024
Medicare's First Round of Drug-Price Negotiation - Measuring SuccessBenjamin N Rome, Aaron S Kesselheim, William B Feldman
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
Clinical Pharmacology and Therapeutics|July 13, 2020
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018Benjamin N Rome, ChangWon C Lee, Aaron S Kesselheim
JAMA Health Forum|July 19, 2024
State Spending Targets for Prescription DrugsCatherine S Hwang, Hussain S Lalani, Benjamin N Rome
JAMA|September 20, 2023
The Inflation Reduction Act and Access to High-Cost Cardiovascular TherapiesDhruv S Kazi, Rishi K Wadhera, Benjamin N Rome
Pageof 14

Showing results (41-50 of 139) with videos related to

Sort By:
Pageof 14
JAMA Health Forum|March 31, 2023
Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021Anjali D Deshmukh, Aaron S Kesselheim, Benjamin N Rome
JAMA|August 19, 2022
New Reforms to Prescription Drug Pricing in the US: Opportunities and ChallengesThomas J Hwang, Aaron S Kesselheim, Benjamin N Rome
JAMA Network Open|January 15, 2026
Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare PatientsJacob S Riegler, Aaron S Kesselheim, Benjamin N Rome
Health Affairs (Project Hope)|May 3, 2021
Frequency Of Generic Drug Price Spikes And Impact On Medicaid SpendingAayan N Patel, Aaron S Kesselheim, Benjamin N Rome
JAMA Internal Medicine|September 23, 2024
Estimated Savings Under the Medicare High-Value Drug List ModelChristopher L Cai, Aaron S Kesselheim, Benjamin N Rome
The New England Journal of Medicine|October 16, 2024
Medicare's First Round of Drug-Price Negotiation - Measuring SuccessBenjamin N Rome, Aaron S Kesselheim, William B Feldman
JAMA|April 18, 2023
Added Therapeutic Benefit of Top-Selling Brand-name Drugs in MedicareAlexander C Egilman, Benjamin N Rome, Aaron S Kesselheim
Clinical Pharmacology and Therapeutics|July 13, 2020
Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018Benjamin N Rome, ChangWon C Lee, Aaron S Kesselheim
JAMA Health Forum|July 19, 2024
State Spending Targets for Prescription DrugsCatherine S Hwang, Hussain S Lalani, Benjamin N Rome
JAMA|September 20, 2023
The Inflation Reduction Act and Access to High-Cost Cardiovascular TherapiesDhruv S Kazi, Rishi K Wadhera, Benjamin N Rome
Pageof 14